AVITA Medical (RCEL) Projected to Post Earnings on Thursday

AVITA Medical (NASDAQ:RCEL) is projected to release its earnings data after the market closes on Thursday, February 27th. Analysts expect AVITA Medical to post earnings of ($0.33) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

AVITA Medical (NASDAQ:RCEL) last posted its earnings results on Thursday, February 13th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.14). AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%. The company had revenue of $18.41 million for the quarter, compared to the consensus estimate of $18.40 million. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AVITA Medical Price Performance

NASDAQ RCEL opened at $9.41 on Tuesday. The firm has a market cap of $246.71 million, a P/E ratio of -3.94 and a beta of 1.55. The stock’s 50-day moving average is $10.34 and its two-hundred day moving average is $10.68. AVITA Medical has a fifty-two week low of $7.51 and a fifty-two week high of $18.93. The company has a debt-to-equity ratio of 9.39, a current ratio of 2.83 and a quick ratio of 2.47.

Insider Buying and Selling

In other news, Director Robert Mcnamara bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $10.09 per share, with a total value of $100,900.00. Following the completion of the transaction, the director now directly owns 45,749 shares in the company, valued at $461,607.41. This represents a 27.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought a total of 12,461 shares of company stock valued at $129,689 over the last three months. 1.82% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on RCEL. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price target on shares of AVITA Medical in a research report on Tuesday, December 24th. Piper Sandler reaffirmed a “neutral” rating and issued a $12.00 price target (up from $9.00) on shares of AVITA Medical in a research report on Friday, November 8th. D. Boral Capital lowered their price target on AVITA Medical from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Finally, Lake Street Capital lowered their price target on AVITA Medical from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.25.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.